cnbc.com

add

Teenagers are often perceived as having little control over their emotions, and while parents may see this as unnecessary angst, it could be due to anxiety.

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

It's a long-awaited win for Eli Lilly after donanemab faced several delays in its path to the market, including an initial rejection from the FDA last year.

CNBC spoke with 11 current and former Pfizer employees, who asked to remain anonymous, about Pfizer's dizzying climb, rapid decline and turnaround strategy.

Harmful E.coli bacteria has been discovered in the U.K.'s River Thames just days before elite rowers are due to compete for the international Henley Regatta.

Paying almost 40% more than in 2014, the average person spends $16.26 out of pocket per prescription, according to the data.

The results and guidance cut come as Walgreens works to slash costs by closing underperforming U.S. stores, among other measures.

Drugmakers showed off data on weight loss and diabetes drugs. Also, Oracle announced the general availability of AI documentation assistant for doctors.

President Joe Biden has made lowering U.S. drug prices a key pillar of his health-care agenda and reelection platform for 2024.

A month ahead of Masimo's annual meeting, activist investor Politan is laying out its case to shareholders to assume board control.

The new plant in Clayton, North Carolina, will be responsible for filling and packaging syringes and injection pens for Wegovy, Ozempic and other drugs.

Some patients with obstructive sleep apnea and obesity who took the highest dose of Zepbound achieved "disease resolution," in the two trials.

The decision lends new credibility to vaping companies’ longstanding claim that their products can help blunt the toll of smoking.

Neurotech startup Paradromics will be putting its brain implant on trial next year, as the race to be the leader in the brain-computer interface space heats up.

AI tech stocks have been on the rage on Wall Street. But here are some events that could lift other Club names higher in the weeks and months ahead.

Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.

More U.S. employers are covering GLP-1s for weight loss, according to a survey. Meanwhile, 25% of health-care VC dollars are going toward companies using AI.

Merck's shot protects against 21 strains of that bacteria to prevent a severe form of pneumococcal disease and a lung infection called pneumonia.

Ashkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly's diabetes injection Mounjaro and obesity drug Zepbound.

With earnings season just about down, our attention turns to economic data for signs of cooling inflation.

Tempus AI rose by as much as 15% on Friday after the health-care diagnostics company priced its IPO at $37, the high end of its offering range.

While lower borrowing costs would likely benefit the overall market, several names in the CNBC Investing Club portfolio could really get a boost.

A new round of Covid shots is coming. Meanwhile, the White House is partnering with Microsoft and Google on cybersecurity for rural hospitals

Companies like The Vitamin Shoppe are leaning more into protein and other supplements as more Americans take GLP-1 weight loss drugs.

If approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.

Counterfeit diabetes test strips have been sold on Amazon and shipped to patients across the U.S., said biotech company Roche.

Abbott has FDA clearance for two new over-the-counter continuous glucose monitoring systems

Moderna is the first company to release positive phase three data on a Covid and flu combination shot, giving it a lead over rivals Pfizer and Novavax.

Donald Trump and President Biden are scheduled for their first presidential debate on June 27.

CityMD is backed by Walgreens Boots Alliance and operates over 100 walk-in urgent care practices in New York and New Jersey.